Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RESEARCH TOOLSreports
Holding RCKT?
Track your performance easily
RCKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.12 - $31.47
Previous CloseN/A
Volume339.48K
Average Volume (3M)1.66M
Market Cap
$1.09B
Enterprise Value$1.53B
Total Cash (Recent Filing)$126.47M
Total Debt (Recent Filing)$48.96M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 06, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding106,337,080
10 Day Avg. Volume1,705,019
30 Day Avg. Volume1,661,801
Standard Deviation0.18
R-Squared0.09
Alpha-0.00735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-664.82
Enterprise Value/Ebitda-6.09
Forecast
1Y Price Target
$43.00Price Target Upside321.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Rocket Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAll Ph1 patients met the pivotal Ph2 primary endpoint, achieving normalized Hgb levels and requiring no more RBC transfusions up to 36 months after RP-L301 infusion.
Pipeline DevelopmentContinued pipeline development with a focus on cardiac indications and strong in-house manufacturing capabilities should support strong long-term growth potential for Rocket.
Regulatory ApprovalRCKT has aligned with the FDA on an accelerated approval pathway for RP-L301.
Bears Say
Approval DelaysApproval for leukocyte adhesion deficiency type I treatment has been delayed to 2025, impacting financial expectations.
Price Target ReductionUpdating the model for the offering lowers the price target from $44 to $40.
Study Initiation DelaysInitiation of RP-L301's pivotal study has been delayed until 2025.
---
Ownership Overview
34.67% Insiders
22.53% Mutual Funds
0.51% Other Institutional Investors
30.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $10.12 and its highest was $31.47 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $1.09B.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.75 by $0.04.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.72.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,337,080 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.75. Following the earnings report the stock price went up 1.159%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 76M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (321.16% Upside)
$43.00 (321.16% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 273.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $302.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.20%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$43.00
▲(321.16% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Sangamo Biosciences
―
Intellia Therapeutics
―
Voyager Therapeutics
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+11.69%
reiterated a buy rating 2 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +11.69% per trade.
---